| Joshua Michael Morris, MD, MA | |
|
601 Colley Ave, Norfolk, VA 23507-1627 | |
| (757) 446-7350 | |
| Not Available |
| Full Name | Joshua Michael Morris |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 601 Colley Ave, Norfolk, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285121855 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101274008 (Virginia) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Entity Name | Evms Academic Physicians And Surgeons Health Services Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003887118 PECOS PAC ID: 5698675510 Enrollment ID: O20040304001377 |
News Archive
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
Glenmark Pharmaceuticals Limited announced today that the US Food and Drug Administration has provided Marketing approval to its partner in US, Salix Pharmaceuticals Limited, for Crofelemer 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in patients with human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART).
Gilead Sciences today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection.
Although the federal government is spending more than $22 billion to encourage hospitals and doctors to adopt electronic health records, it has failed to put safeguards in place to prevent the technology from being used for inflating costs and overbilling, according to a new report by a federal oversight agency (Abelson and Creswell, 1/8).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Michael Morris, MD, MA 601 Colley Ave, Norfolk, VA 23507-1627 Ph: (757) 446-7350 | Joshua Michael Morris, MD, MA 601 Colley Ave, Norfolk, VA 23507-1627 Ph: (757) 446-7350 |
News Archive
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
Glenmark Pharmaceuticals Limited announced today that the US Food and Drug Administration has provided Marketing approval to its partner in US, Salix Pharmaceuticals Limited, for Crofelemer 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in patients with human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART).
Gilead Sciences today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection.
Although the federal government is spending more than $22 billion to encourage hospitals and doctors to adopt electronic health records, it has failed to put safeguards in place to prevent the technology from being used for inflating costs and overbilling, according to a new report by a federal oversight agency (Abelson and Creswell, 1/8).
› Verified 3 days ago
Daniel L Noffsinger, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 880 Kempsville Rd, Suite 2200, Norfolk, VA 23502 Phone: 757-466-6350 Fax: 757-466-9262 | |
Anna Hayes Nutter, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 825 Fairfax Ave, Hofheimer Hall. Suite 528, Norfolk, VA 23507 Phone: 757-446-7350 | |
Negar Nikki Sadr, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 844 Kempsville Rd, Suite 208, Norfolk, VA 23502 Phone: 757-461-3890 Fax: 757-461-0836 | |
Alana Michelle Chakrabarti, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 825 Fairfax Ave Ste 310, Norfolk, VA 23507 Phone: 757-446-7979 Fax: 757-446-8907 | |
Malena C Sample, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5280 Henneman Dr, Norfolk, VA 23513 Phone: 757-395-4455 Fax: 757-233-1792 | |
Theresa W Whibley, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 400 Gresham Dr, Suite 811, Norfolk, VA 23507 Phone: 757-623-3845 Fax: 757-623-0547 | |
Gloria T Too, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 825 Fairfax Ave, Suite 310, Norfolk, VA 23507 Phone: 757-446-7900 Fax: 757-446-7464 |